Phase 1Completed

Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Simvastatin (a Sensitive CYP3A4 Substrate) in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI

Sponsor
AstraZeneca (Industry)
Enrollment
52 enrolled
Conditions
Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling - AZD9291; Simvastatin; AZD9291 tablet dosing; Pharmacokinetic sampling - simvastatin; Pharmacokinetic sampling - AZ5140 and AZ7550
Ages
adults, older adults
Registry
NCT02197234, EUCTR2014-002070-36

Full record on ClinicalTrials.gov

From the registry

This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior therapy with an approved EGFR tyrosine kinase inhibitor (TKI) agent. Part A will assess the effect of AZD9291 on the pharmacokinetic (PK) parameters of simvastatin and simvastatin acid, following multiple oral dosing of AZD9291 in a fasted state. Part B will allow patients further access to AZD9291 after the PK phase (Part A) and will provide for additional safety data collection. All patients from Part A who completed treatment may continue to receive AZD9291 80 mg once daily until: disease progression; they are no longer deriving clinical benefit; or any other reason.

Primary outcomes

  • Cmax of Simvastatin
  • AUC of Simvastatin

History

  1. Last registry update

  2. Study completion

  3. Results first posted

  4. Primary completion

  5. Started

  6. Registered